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ABSTRACT
The aim was to evaluate serum levels of circulating cell-free nucleosomes (ccfn) 
containing a variety of epigenetic signals including 5-methylcytosine DNA, histone 
modifications H3K9Me3, H3K9Ac, H3S10PO4, H3K36Me3, H4K20Me3, H4PanAc and 
pH2AX, nucleosome variant H2AZ and nucleosome adducts with HMGB1 and EZH2 as 
well as ccfn per se, in addition to develop and evaluate predictor models based on 
the above mentioned ccfn and including serum levels of carcinoembryonic antigen 
(CEA), in early detection of colorectal cancer (CRC). 
Blood-samples were collected from 4,105 individuals undergoing colonoscopy. 
Serum levels of ccfn and CEA were determined using enzyme-linked immunosorbent 
assays platforms. Individual assessment of levels of ccfn showed area under the 
receiver operating characteristic curve (AUCROC) = 0.525–0.576 in discrimination of 
individuals with CRC from individuals with non-malignant findings. Predictor models 
including ccfn containing 5-methylcytosine DNA, CEA, age and gender improved results 
(AUCROC = 0.736, sensitivity = 0.37 at specificity = 0.90). Further improvement 
was achieved in discrimination of individuals with CRC from individuals with clean 
colorectum (AUCROC = 0.840, sensitivity = 0.57 at specificity = 0.90). The levels 
of ccfn among patients with CRC appeared to be stage-independent. In conclusion, 
the performance of the developed predictor models is potentially promising in early 
detection of CRC.
INTRODUCTION
During the last decade, major progress has emerged 
in diagnostics and treatment of colorectal cancer (CRC), 
but the disease still poses a major challenge to public 
health. CRC is one of the most frequent types of cancer 
and is estimated to account for some 700,000 deaths per 
year worldwide [1].
To counter this challenge, national population-based 
screening programs for CRC have been implemented in 
several countries, including Denmark [2]. Screening has 
been shown to reduce incidence and improve overall survival 
by early detection of CRC and by primary prevention 
through removal of pre-cancerous lesions (adenomas) [3, 4].
Colonoscopy is considered the Gold Standard in 
screening for CRC due to high diagnostic accuracy and 
the possibility of intervention (polypectomy, biopsy, 
etc.) during the examination. However, the feasibility of 
a colonoscopy-based screening program is challenged 
by capacity requirements, costs and side-effects, such 
as abdominal pain, transient cardiovascular changes, 
bleeding episodes and bowel perforation [5]. Therefore, 
fecal occult blood tests (FOBT) are often used to identify 
high-risk individuals, who should be offered subsequent 
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diagnostic colonoscopy. At present, the most frequently 
applied FOBT in national screening programs is fecal 
immunochemical test (FIT) [2]; the sensitivity of FIT for 
detection of CRC is 0.79  at a specificity of 0.94 [6]. 
Despite the widespread use of feces-based tests 
in screening for CRC, the tests are challenged by low 
compliance; compliance for FIT is around 60% [7, 8] 
leading to a diminished effectiveness of screening. Hence, 
blood-based biomarkers, as an alternative or supplement 
to feces-based screening tests, have been subject to 
intense research. Blood samples are easy to retrieve, and 
the acceptance within a screening population consisting 
of mostly healthy individuals are higher compared with 
fecal samples required for FIT [9, 10]. Blood-based 
biomarkers are a heterogeneous group of various proteins, 
epigenetic markers, transcriptomes, metabolomes and 
circulating tumor-derived DNAs, and some have shown 
promising association to early stages of CRC  [11–14]. In 
particular combination of various biomarkers have shown 
complimentary performance in discrimination of CRC 
[15–17], and the application of data fusion to incorporate 
information regarding age, gender, health-status, etc. to 
the determination of biomarkers has further increased the 
performance of some biomarkers [18]. 
Recent studies indicate that changes in levels of 
circulating cell-free nucleosomes (ccfn) may have potential 
as  biomarkers for CRC [12, 19]. Nucleosomes consist 
of small DNA chains of approximately 147 bp, wrapped 
around a histone octamer that contains pairs of H2A, H2B, 
H3 and H4 proteins. Nucleosomes are bound together with 
linker DNA, linker histones and other non-histone proteins 
to form intracellular chromatin. During cell death the 
linker DNA is digested and nucleosomes are released into 
the circulation as ccfn, which can be detected by enzyme-
linked immunosorbent assays (ELISA) [12]. Changes in 
levels of total ccfn have been shown in the circulation of 
individuals with cancer as a result of increased cell turn-
over [20]. Furthermore, altered epigenetic control of gene 
expression (DNA methylation, modifications in histone 
structure, etc.) plays a crucial role in carcinogenesis 
[21]. Changes in levels of ccfn that contain CRC-specific 
epigenetic alterations can be detected in individuals with 
CRC [12, 19], and possess the potential to be a valuable 
biomarker in early detection of CRC. 
The aim of the present study was to assess serum 
levels of ccfn containing 5-methylcytosine DNA (5 
mC), histone H3 tri-methylated at lysine 9 (H3K9Me3), 
histone H3 acetylated at lysine 9 (H3K9Ac), histone H3 
phosphorylated at serine 10 (H3S10PO4), histone H3 
tri-methylated at lysine 36 (H3K36Me3), histone H4 
tri-methylated at lysine 20 (H4K20Me3), pan-acetylated 
H4 (H4PanAc), histone variant H2AX phosphorylated 
at serine 139 (pH2AX), nucleosome variant H2AZ 
(H2AZ), nucleosome adducted with HMGB1 (HMGB1) 
and EZH2 (EZH2) as well as ccfn per se. In addition, 
development of predictor models based on serum levels 
of the above mentioned ccfn and including serum levels 
of carcinoembryonic antigen (CEA), age and gender were 
evaluated in early detection of CRC.
RESULTS
A total of 4,105 individuals referred to diagnostic 
colonoscopy were included in the study comprising 441 
individuals with CRC (279 with colon cancer and 162 with 
rectal cancer), 143 with primary cancer of non-colorectal 
origin and 342 with high risk adenomas (Figure 1). The 
population included 1,964 men and 2,141 women with 
median age of 64 (18–95). 
Figure 2 shows the distribution of optical density 
(OD) measurements of 5 mC according to diagnostic 
groups. A significant trend (p < 0.001) of decreased levels 
in individuals with CRC, other cancers and colorectal 
adenomas are shown compared with individuals with other 
non-malignant findings and clean colorectum.
Spearman rank correlations were used to assess the 
association between the ccfn. Correlation coefficients 
were found to be > 0.5 except for H3K9Me3 where 
the correlation coefficients with the other ccfn were > 
0.3 (data not shown). Figure 3 shows a scatter plot of 
OD-measurements of 5 mC vs. ccfn per se illustrating 
the correlation between the two measurements with a 
correlation coefficient of 0.81 (p < 0.001).
Results of the assessment of influence of disease 
stage, gender and comorbidity on levels of ccfn and CEA 
are presented in Table 1. An independence of disease 
stage (CRC stage I–IV) was shown as comparisons 
of levels of the ccfn in the four disease groups did not 
reach significance. As expected, levels of CEA were 
significantly stage dependent with higher levels associated 
to higher stage. The level of H3S10PO4 was the only ccfn 
that showed an association to gender with significantly 
lower levels in women compared to men; however, 
all ccfn had R2 < 0.02 (Table 1). Regarding influence 
of comorbidity, levels of 5 mC, H4PanAc, H3K9Ac, 
H3S10PO4, H3K36Me3, EZH2, HMGB1 and CEA (lung 
disease), H3K9Me3 and pH2AX (cardiovascular disease), 
and H3K9Me3 (diabetes I/II) were significantly lower 
in individuals with comorbidity compared to levels in 
individuals with no comorbidity and clean colorectum; 
R2 < 0.05 (Table 1). In the comparison of individuals with 
rheumatic disease to individuals with no comorbidity and 
clean colorectum, significance was not reached for levels 
of any ccfn or CEA (Table 1). 
A weak dependence of levels of ccfn on age was 
shown with decreasing levels at increasing age (R2 < 0.02)
Results from the univariate analysis of the ccfn and 
CEA regarding the discrimination of individuals with 
CRC (endpoint 1), individuals with CRC and high-risk 
adenomas (endpoint 2), individuals with cancer (endpoint 
3), individuals with high risk adenomas (endpoint 4) and 
individuals with other cancers excluding CRC (endpoint 5) 
Oncotarget10249www.impactjournals.com/oncotarget
are shown in Table 2. For endpoint 1, the area under the 
receiver operating characteristic (ROC) curve (AUCROC) 
was in the range of 0.525–0.576; results for H3K36Me3 
and H4K20Me2 were not significant, but significance 
was reached for the remaining ccfn. Regarding endpoint 
2 and 3, the AUCROC was found to be in the range of 
0.526–0.574; results for all ccfn were significant. AUCROC 
was 0.533–0.584 for endpoint 4; results for all ccfn 
were significant except ccfn per se. Results for endpoint 
5 showed insignificant result for the majority of ccfn 
with the exception of ccfn per se, 5 mC, H3K9Me3 and 
pH2AX; AUCROC was 0.508–0.564.   
Results from the predictor models (AUCROC with 
associated p-value and sensitivities at specificities 0.70, 
0.80, and 0.90) are presented in Table 3. The ccfn with 
independent significance and thus included in the predictor 
model 1–5 (based on endpoint 1–5, respectively) was 5 
mC. The discrimination of individuals with CRC from 
individuals with non-malignant findings (endpoint 1) 
yielded AUCROC = 0.736 (sensitivity = 0.37 at specificity 
= 0.90) when applying predictor 1. Similar AUCROC was 
shown in the discrimination of individuals with cancer 
(CRC and other cancers) (endpoint 3) and individuals with 
other cancers (excluding CRC) (endpoint 5); AUCROC= 
0.736 (sensitivity = 0.37 at specificity = 0.90) and AUCROC= 
0.741 (sensitivity 0.39 at specificity 0.90), respectively. In 
comparison, the discrimination of individuals with high 
risk adenomas (endpoint 4) and individuals with CRC and 
high risk adenomas (endpoint 2) from individuals with non-
malignant findings were lower; AUCROC = 0.646 (sensitivity 
= 0.21 at specificity = 0.90) and AUCROC= 0.691 (sensitivity 
= 0.28 at specificity = 0.90), respectively.
To further explore the performance of the predictor 
models based on serum levels of ccfn, CEA, age and 
gender, subgroup-predictor models were developed. 
Compared to endpoint 1, subgroup-predictor model 
based on the discrimination of individuals with CRC 
from individuals with clean colorectum showed an 
improved AUCROC and associated sensitivity (AUCROC = 
0.840, sensitivity = 0.57 at specificity = 0.90). Subgroup-
predictor model based on the discrimination of individuals 
with early stage CRC (stage I or II) and late stage CRC 
(stage III or IV) from individuals with clean colorectum 
resulted in a difference in AUCROC of 0.026 in favor of late 
stage CRC. Eliminating CEA from the subgroup-predictor 
models resulted in a difference of 0.026 in favor of early 
stage CRC (data not shown). 
Finally, a subgroup predictor model based on the 
discrimination of individuals with CRC stage I + II + 
III from individuals with non-malignant findings, thus 
eliminating the influence of metastatic disease, showed 
AUCROC = 0.711, sensitivity = 0.31 at specificity = 0.90.
Figure 4 shows ROC curves and AUCROC of 
predictor model 1 and 2 and subgroup-predictor models 
Table 1: R2 and p-values of the difference in serum levels of modified circulating cell-free 
nucleosomes and carcinoembryonic antigen (CEA) between individuals with stage I–IV colorectal 
cancer (CRC), between individuals with comorbidity (cardiovascular disease, diabetes I/II, lung 
disease and rheumatic disease) and healthy individuals, and between gender and age in healthy 
individuals
CRC Co-morbidity Demographics
CRC stages Cardiovascular Diabetes I/II Lung Rheumatic Age Gender
R2 p-value R2 p-value R2 p-value R2 p-value R2 p-value R2 p-value R2 p-value
Parametera
ccfn per se 0.0060 0.4517 0.0260 0.0503 0.0238 0.9370 0.0248 0.1846 0.0238 0.8862 0.0071 0.0067 0.0010 0.2980
5mC 0.0040 0.6239 0.0320 0.3676 0.0315 0.8800 0.0348 0.0153 0.0318 0.4676 0.0151 < 0001 0.0015 0.2122
H3K9Me3 0.0148 0.0900 0.0155 0.0325 0.0155 0.0315 0.0141 0.1359 0.0130 0.6581 0.0083 0.0032 0.0016 0.2001
H3K9Ac 0.0060 0.4506 0.0190 0.5074 0.0191 0.4145 0.0215 0.0273 0.0188 0.9918 0.0062 0.0114 0.0007 0.4048
H3S10PO4 0.0060 0.4542 0.0172 0.1177 0.0158 0.9394 0.0193 0.0124 0.0159 0.6600 0.0059 0.0136 0.0039 0.0431
H3K36Me3 0.0048 0.5541 0.0127 0.4804 0.0124 0.9788 0.0153 0.0244 0.0124 0.9948 0.0038 0.0469 0.0024 0.1152
H4K20Me3 0.0061 0.4416 0.0160 0.0548 0.0146 0.2867 0.0148 0.2263 0.0147 0.2510 0.0075 0.0053 0.0024 0.1148
H4PanAc 0.0055 0.4931 0.0103 0.2554 0.0101 0.3364 0.0123 0.0284 0.0097 0.7029 0.0034 0.0603 0.0014 0.2211
pH2AX 0.0052 0.5133 0.0246 0.0155 0.0216 0.4350 0.0233 0.0613 0.0213 0.7535 0.0056 0.0160 0.0029 0.0815
H2AZ 0.0046 0.5743 0.0201 0.1532 0.0190 0.6158 0.0207 0.0730 0.0190 0.6946 0.0075 0.0052 0.0036 0.0543
HMGB1 0.0119 0.1552 0.0209 0.0972 0.0194 0.9220 0.0217 0.0453 0.0195 0.6188 0.0072 0.0062 0.0015 0.2174
EZH2 0.0067 0.3993 0.0209 0.0626 0.0194 0.3543 0.0235 0.0047 0.0195 0.3337 0.0062 0.0109 0.0034 0.0605
CEA 0.2046 < 0001 0.0108 0.3492 0.0105 0.5051 0.0207 < 0001 0.0109 0.2928 0.0053 0.0193 0.0004 0.5461
a ccfn: circulating cell-free nucleosomes, 5mC: ccfn containing 5-methylcytosine DNA, H3K9Me3: histone H3 tri-methylated at lysine 9, H3K9Ac: histone 
H3 acetylated at lysine 9, H3S10PO4: histone H3 phosphorylated at serine 10, H3K36Me3: histone H3 tri-methylated at lysine 36, H4K20Me3: histone H4 
tri-methylated at lysine 20, H4PanAc: pan-acetylated H4, pH2AX: histone variant H2AX phosphorylated at serine 139, H2AZ: nucleosome variant H2AZ, 
HMGB1: nucleosome adducted with HMGB1, EZH2: nucleosome adducted with EZH2.
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based on the discrimination of early and late stage 
CRC from individuals with non-malignant findings, 
the discrimination of individuals with CRC from 
individuals with clean colorectum and the discrimination 
of individuals with CRC and high risk adenomas from 
individuals with clean colorectum.
DISCUSSION
Assessed individually, the determined ccfn have 
a weak ability to discriminate individuals with high risk 
adenomas and cancer including CRC from individuals 
with non-malignant findings (AUCROC = 0.508–0.584). 
However, the performance was substantially improved 
when predictor models based on endpoint 1–5 were 
constructed combining levels of ccfn determinations (5 
mC) with levels of CEA, age and gender. The performance 
in discrimination of individuals with CRC from 
individuals with non-malignant findings yielded AUCROC 
of 0.736. This is in line with previous research showing 
association between specific ccfn alterations and CRC 
[12, 19, 22], and the improved performance by 
combination of ccfn as biomarker for cancer [17, 19]. 
The performance of the predictor models in 
discrimination of individuals with high risk adenomas 
and CRC (endpoint 2) and individuals with high risk 
adenomas exclusively (endpoint 4) obtained AUCROC 
= 0.691 and AUCROC = 0.646, respectively. The inferior 
AUCROC compared with the performance in discrimination 
of individuals with CRC may be explained by the non-
invasive nature of adenomas compared to carcinomas, 
which could cause a reduction in release of altered ccfn 
into the circulation. Supporting this speculation, previous 
research has showed that the profile of epigenetic alterations 
in tissue from colorectal adenomas and CRC are similar, 
and the expression of some alterations is higher in tissue 
from CRC compared to tissue from adenomas [23, 24].
In comparison to the performance in discrimination 
of individuals with CRC, the performance in 
discrimination of individuals with cancer including CRC 
(endpoint 3) and individuals with other cancers excluding 
CRC (endpoint 5) obtained similar results, AUCROC = 
0.736 and AUCROC = 0.741, respectively. This may indicate 
that ccfn represent epigenetic changes associated with 
carcinogenesis in general and not only carcinogenesis of 
CRC. However, the findings regarding discrimination of 
individuals with other cancers are based on a relatively 
small number of individuals, and further studies are 
needed to draw a final conclusion. 
The performance of the predictor models was 
further improved in discrimination of individuals with 
Table 2: Area under the receiver operating characteristic (ROC) curve (AUCROC) and p-values 
of univariate logistic regression analysis of endpoint 1–5a based on serum levels of circulating 
cell-free nucleosomes and carcinoembryonic antigen (CEA)
Endpointa
1 2 3 4 5
AUCROC P-value AUCROC P-value AUCROC P-value AUCROC P-value AUCROC P-value
Parameterb
ccfn per se 0.559 < 0001 0.549 < 0001 0.557 < 0001 0.533 0.0911 0.552 0.0480
5mC 0.574 < 0001 0.574 < 0001 0.571 < 0001 0.563 < 0001 0.564 0.0112
H3K9Me3 0.539 0.0050 0.546 < 0001 0.541 0.0007 0.551 0.0031 0.554 0.0261
H3K9Ac 0.567 < 0001 0.565 < 0001 0.560 < 0001 0.556 0.0009 0.536 0.1143
H3S10PO4 0.547 0.0025 0.543 < 0001 0.539 0.0021 0.534 0.0089 0.520 0.2871
H3K36Me3 0.525 0.1010 0.542 0.0004 0.526 0.0434 0.557 0.0008 0.532 0.1691
H4K20Me3 0.526 0.0707 0.546 0.0003 0.531 0.0271 0.563 0.0011 0.542 0.1455
H4PanAc 0.544 0.0110 0.554 < 0001 0.546 0.0048 0.561 0.0021 0.543 0.1554
pH2AX 0.576 < 0001 0.574 < 0001 0.573 < 0001 0.562 0.0002 0.564 0.0487
H2AZ 0.540 0.0115 0.563 < 0001 0.536 0.0088 0.584 < 0001 0.530 0.2821
HMGB1 0.558 < 0001 0.561 < 0001 0.556 < 0001 0.557 0.0015 0.552 0.0602
EZH2 0.540 0.0096 0.542 0.0002 0.531 0.0095 0.542 0.0079 0.508 0.3867
CEA 0.662 < 0001 0.606 < 0001 0.668 < 0001 0.530 0.1862 0.688 < 0001
a Endpoint 1: Individuals with colorectal cancer (CRC) vs. individuals with non-malignant findings; Endpoint 2: Individuals with CRC and high risk 
adenomas vs. individuals with non-malignant findings excluding individuals with high risk adenomas; Endpoint 3: Individuals with cancer vs. individuals 
with non-malignant findings; Endpoint 4: Individuals with high risk adenomas vs. individuals with non-malignant findings excluding individuals with 
high risk adenomas; Endpoint 5: Individuals with cancer excluding CRC vs. individuals with non-malignant findings.
b ccfn: circulating cell-free nucleosomes, 5mC: ccfn containing 5-methylcytosine DNA, H3K9Me3: histone H3 tri-methylated at lysine 9, H3K9Ac: 
histone H3 acetylated at lysine 9, H3S10PO4: histone H3 phosphorylated at serine 10, H3K36Me3: histone H3 tri-methylated at lysine 36, H4K20Me3: 
histone H4 tri-methylated at lysine 20, H4PanAc: pan-acetylated H4, pH2AX: histone variant H2AX phosphorylated at serine 139, H2AZ: nucleosome 
variant H2AZ, HMGB1: nucleosome adducted with HMGB1, EZH2: nucleosome adducted with EZH2.
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CRC from individuals with clean colorectum which 
yielded AUCROC of 0.840 (sensitivity 0.57 at specificity 
0.90). This discrimination was performed to provide an 
indication of the maximum potential performance of the 
predictor models in a screening setting, as the performance 
based on endpoint 1–5 might be underestimated due to the 
design of the study with the inclusion of a symptomatic 
population. Thus, the individuals of the control group are 
symptomatic. 
The progress of CRC does not influence levels of 
ccfn as variations in levels of ccfn between the groups of 
individuals of the four stages of CRC were insignificant 
(Table 1). The performance of predictor model 1 in 
discrimination of individuals with early stage CRC 
compared to discrimination of individuals with late stage 
CRC is small, and the difference in AUCROC in favor of 
late stage disease reverts to favor early stage disease when 
CEA is eliminated from the predictor model. Furthermore, 
similar performance of the predictor model was obtained 
when metastatic CRC (stage IV) was eliminated from the 
discrimination. Altogether, this indicates that levels of 
ccfn are independent of progression of CRC. This might 
be explained by epigenetic changes playing a qualitative 
role in carcinogenesis. Hence, it is speculated that the 
amount of DNA and histone changes in the nucleosomes is 
persistent from the initial neoplastic transformation to the 
advanced cancer stage making ccfn ideal as a biomarker 
for early detection of CRC. The independence of disease 
stage would be an advantageous quality as potential blood-
based screening-biomarker for CRC. 
Exclusively, 5 mC was the only ccfn included in the 
predictor models. This may be explained by the relatively 
strong correlations observed between the ccfn (Spearman 
rank correlation) indicating a close and complex 
interaction between the different histone modifications, 
variants and nucleosomes containing methylated DNA. 
The effect of a single nucleosomic modification on the 
development of CRC may be linked to the effect of 
numerous modifications in a dynamic complex of various 
epigenetic regulatory mechanisms [25].
In this study, the blood samples were collected 
before colonoscopy but after bowel preparation which 
potentially could affect levels of biomarkers and thereby 
might induce bias. However, it has been shown that levels 
of ccfn are not influenced by bowel preparation [26] 
which supports the potential use of ccfn in screening for 
CRC even further. 
Levels of ccfn decline with increasing age although 
the overall influence of age is minor as the proportion of 
the explained variance is very low. In general, the effect 
of aging on epigenomic regulation of DNA is complex 
and involves interaction between multiple regulatory 
Table 3: Assessment of predictor models and subgroup-predictor models: Area under the receiver 
operating characteristic (ROC) curve (AUCROC) and sensitivity at specificities 0.7, 0.8 and 0.9
Sensitivity
Specificity
0.7 0.9 0.8
Sensitivity Sensitivity Sensitivity
Predictor model AUCROC
Endpoint 1 (A) 0.736 0.615 0.510 0.370
Endpoint 2 (B) 0.691 0.571 0.420 0.284
Endpoint 3 (C) 0.736 0.622 0.524 0.368
Endpoint 4 (D) 0.646 0.480 0.360 0.205
Endpoint 5 (E) 0.741 0.636 0.566 0.385
Endpoint 1/stage I-II (Fa) 0.716 0.596 0.484 0.329
Endpoint 1/stage III-IV (Fb) 0.755 0.633 0.535 0.409
Endpoint 1/stage I-III (Fc) 0.711 0.566 0.451 0.310
Endpoint 1 vs clean colorectum (G) 0.840 0.810 0.737 0.565
Endpoint 1/stage I-II vs clean colorectum (Ha) 0.832 0.791 0.720 0.551
Endpoint 1/stage III-IV vs clean colorectum (Hb) 0.858 0.828 0.753 0.577
Endpoint 2 vs clean colorectum (I) 0.813 0.793 0.693 0.506
Letters in parenthesis refer to ROC curves shown in Figure 4. Circulating cell-free nucleosomes containing 5-methylcytosine 
DNA and CEA were included as explanatory variables along with age and gender in all five predictor models. Endpoint 1: 
Individuals with colorectal cancer (CRC) vs. individuals with non-malignant findings; Endpoint 2: Individuals with CRC and 
high risk adenomas vs. individuals with non-malignant findings excluding individuals with high risk adenomas; Endpoint 
3: Individuals with cancer vs. individuals with non-malignant findings; Endpoint 4: Individuals with high risk adenomas vs. 
individuals with non-malignant findings excluding individuals with high risk adenomas; Endpoint 5: Individuals with cancer 
excluding CRC vs. individuals with non-malignant findings.
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proteins and pathways. During aging, a general loss of 
heterochromatin has been shown which causes a loss of 
repressive histone marks and methylated DNA [27]. This 
supports the present findings of decreasing levels of ccfn 
with increasing age. The effect of gender on levels of ccfn 
was concluded to be of limited importance since only levels 
of H3S10PO4 showed difference between genders and all 
ccfn obtain R2-values < 0.02 . Lung disease, cardiovascular 
disease and diabetes I/II were found to affect levels of 
some ccfn, but again the influence was found to be minor. 
The levels of ccfn were measured in output from 
ELISA as OD values. However, the assay does not 
distinguish between the numbers of times a specific 
alteration appears in a single nucleosome. Hence, the OD 
output from the ELISA detection is not equivalent to a 
concentration of ccfn, but is an expression of the amount 
of altered epigenetic control of gene expression in serum 
samples.
The Sept9 DNA methylation assay was the first 
blood-based CRC screening test to be approved for use in 
an average risk population [28] with a reported sensitivity 
of 0.48 at specificity 0.915 [29] in an asymptomatic 
population. The detection rates are correlated to the 
progression of CRC as advanced disease leads to increased 
detection rates, and the detection rates for high risk 
adenomas are low. The performance of the Sept9 DNA 
methylation assay has been shown to be influenced  by 
age and comorbidities such as diabetes [30]. A direct 
comparison between the levels of ccfn as blood-based 
biomarker for early detection of CRC found in this study 
with the performance of the Sept9 DNA methylation 
assay is not possible due to differences in study-design. 
However, the independence of progression of CRC, the 
minor influence of co-morbidity and age, the relatively 
high performance in discrimination of individuals 
with high risk adenomas and the high performance in 
discrimination of individuals with CRC from individuals 
with clean colorectum found in this study, may indicate 
that levels of ccfn are competitive to Sept9 DNA 
methylation assay as blood-based biomarkers for early 
detection of CRC. However, further studies based on 
asymptomatic populations are needed to confirm the 
results of this study.
The epigenetic regulation of DNA composes a 
complex interaction between different modifications 
leading to diverse patterns of gene expression emerging 
from the same genome [25]. The ccfn evaluated in this 
study are all associated with CRC, but are not separate 
events in the epigenetic regulation of the genome during 
carcinogenesis, reflecting only a tip of the iceberg of the 
entire epigenetic alterations leading to CRC. This explains 
the finding of relatively strong correlations between the 
ccfn. 
In conclusion, the performance of the designed 
predictor models is potentially promising in early 
detection of CRC. Addition of biomarkers of different 
quality, for example protein biomarkers, to the present 
predictor-model based on epigenetic modifications 
Figure 1: Flowchart showing the inclusion of individuals in the study.
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might improve the performance even further, making 
the biomarker-combination potentially competitive to 
FIT and thereby beneficial supplement in a screening 
program. Another future aspect is the possible supplement 
of the predictor-models to FIT in order to potentially 
improve performance of current screening-programs. 
However, further studies are needed to support these 
proposals.
MATERIALS AND METHODS
The study was a part of the Endoscopy II Project, 
which has been approved by the Ethics Committee of 
the Capital Region of Denmark (H-3-2009-110) and the 
Danish Data Protection Agency (2007-58-0015) and 
performed according to the Helsinki II Declaration.
Individuals scheduled for first time ever diagnostic 
colonoscopy due to symptoms attributable to CRC at seven 
hospitals in Denmark (Bispebjerg, Herning, Hillerød, 
Horsens, Hvidovre, Randers, and Aarhus hospitals) 
were included from 1 May 2010 to 30 November 2012. 
Inclusion criteria were age ≥ 18, symptoms attributable 
to CRC and signed informed consent. Exclusion criteria 
were previous malignant disease, previous large bowel 
adenoma, member of a Hereditary Non-Polyposis 
Colorectal Cancer or Familiar Adenomatosis Polyposis 
family and surgical intervention within 3 months before 
inclusion. Furthermore, individuals unable to understand 
the written study-information were excluded from the 
study. On the day of the colonoscopy an informed consent 
was signed by the participating individual, and personal 
data (age, gender, comorbidity (cardiovascular disease, 
lung disease, rheumatic disease, and diabetes I/II)) was 
recorded by a dedicated research nurse. Blood samples for 
serum were collected before colonoscopy according to a 
validated Standard Operating Procedure and subsequently 
centrifuged at 3,000 X G for 10 minutes at 21°C. The 
supernatant serum was transferred to separate freezing 
tubes leaving 0.5 cm of serum untouched above the buffy-
coat to avoid contamination from white cells and platelets. 
Serum samples were labelled with unique barcodes to 
ensure subsequent identification (FreezerWorks®), and 
Figure 2: Box-plots with median, 1st and 3rd quartile showing the distribution of optical density (OD) values of 
circulating cell-free nucleosomes containing 5-methylcytosine DNA (5 mC) according to diagnostic groups. A significant 
trend (p < 0.001) of decreased levels in individuals with CRC, other cancers and colorectal adenomas are shown compared with individuals 
with other non-malignant findings and clean colorectum.
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all samples were stored at −80°C under 24/7 electronic 
surveillance.
Findings at colonoscopy including pathological 
diagnosis were registered in a database in addition to 
the obtained personal data. After final data compilation 
a rigorous audit of the database was performed to ensure 
the validity, and the database was locked. 
The endpoints considered were:
Endpoint 1: Individuals with CRC (all stages), 
Endpoint 2: Individuals with CRC and high risk adenomas, 
Endpoint 3: Individuals with cancer (CRC and cancer of 
non-colorectal origin). Endpoint 4: Individuals with high 
risk adenomas, Endpoint 5: Individuals with other cancers 
(excluding CRC).
The control group for endpoint 1, 3 and 5 was 
individuals with non-malignant findings including low and 
high risk adenomas. The control group for endpoint 2 and 
4 was individuals with non-malignant findings including 
low risk adenomas and excluding high risk adenomas.
The criteria for high risk adenoma were: ≥ 1 cm 
in size or ≥ 3 lesions or villous component or high grade 
dysplasia [31].
The panel of 12 ccfn assays were constructed based 
on literature searches on published results for epigenetic 
modifications associated with carcinogenesis of CRC as 
well as previous experiences of ccfn modifications and 
adducts associated with CRC.
Ccfn and CEA levels in the serum samples were 
determined by  Belgian Volition SPRL, Isnes, Belgium 
using Nu.QTM ELISA platforms as previously described 
[12]. In brief, ccfn were captured onto an ELISA plate using 
an anti-nucleosome antibody and the level of nucleosomes 
containing a particular epigenetic feature was quantified by 
binding of a separate detection antibody directed to bind to 
the epigenetic feature of the nucleosomes. 
Absolute mass or other SI units of ccfn have not yet 
been defined, and no International Standard preparations, 
absolute or relative, have been reported. Therefore, the 
performed measurements of levels of ccfn and CEA were 
expressed in the output from the ELISA detection as OD. 
All ELISA measurements on each serum sample were 
performed in duplicate and results used for the statistical 
analysis were expressed as the mean of the duplicate 
measurement. 
Figure 3: Scatter plot showing optical density (OD) values of circulating cell-free nucleosomes containing 
5-methylcytosine DNA (5 mC) vs. total circulating cell-free nucleosomes per se (ccfn per se) illustrating the correlation 
between the two measurements, r = 0.81 (p < 0.001).
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Only results from individuals with a complete set of 
biomarker determinations (5 mC, H3K9Me3, H3K9Ac, 
H3S10PO4, H3K36Me3, H4K20Me3, H4PanAc, pH2AX, 
H2AZ, HMGB1, EZH2, ccfn per se and CEA) were used 
for statistical analyses. The flow chart (Figure 1) presents an 
overview of individuals recruited and included or excluded 
in the study. Missing biomarker determinations were due to 
lack of sample material and were missing at random.
Statistics
Comparison of ccfn levels between CRC stages, 
co-morbidities, gender and age were done using linear 
modelling with the ccfn levels log transformed. Analysis 
of co-morbidities, gender and age were restricted to 
individuals with a clean colorectum result. In addition, 
the analysis of co-morbidities was adjusted for age and 
gender. The results of these analyses are presented by 
the R2 value (reflecting proportion of the total variation 
explained by the model) and the p-value. 
All endpoints considered are binary as described 
above. Logistic regression analysis with the endpoints as 
the dependent variable and the biomarkers as explanatory 
variables has been done. Age and gender have also been 
included as explanatory covariates. Initial analyses 
were done for each explanatory variable as a univariate 
analysis, and then multivariate analysis was performed 
combining all explanatory variables as well as age and 
gender, reducing the model to only include statistically 
significant ccfn. The final model was developed using 
10-fold cross validation with backwards selection 
using the Akaike information criterion. The results are 
presented by the ROC curves with AUCROC as a measure 
of discrimination and the sensitivities at pre-specified 
specificities (70, 80, and 90%). For each endpoint, a 
predictor, i.e. a linear combination of the significant 
explanatory covariates, has been established; exclusively, 
5 mC and CEA were included as explanatory variables 
along with age and gender in all five predictor models. 
Subgroup analyses restricted to early stage CRC (stage 
I or II), late stage CRC (stage III or IV), and restricting 
the controls to individuals with clean colorectum have 
been performed. P-values less than 5% are considered 
significant. Database management and calculations have 
Figure 4: Receiver operating characteristic (ROC) curves and area under the ROC curve (AUCROC) of predictor models and subgroup-
predictor models based on the discrimination of endpoint 1 (A), endpoint 2 (B), the discrimination of early stage CRC (Fa) and late stage 
CRC (Fb) from individuals with non-malignant findings, the discrimination of individuals with CRC (G) from individuals with clean 
colorectum, and the discrimination of individuals with CRC and high risk adenomas (I) from individuals with clean colorectum. Letters in 
parenthesis refer to results from Predictor models listed in Table 3.
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been done using SAS (v9.4, SAS Institute, Cary, N.C., 
USA) and R (Frank E Harrell Jr (2016). Rms: Regression 
Modeling Strategies. R package version 4.4-2 http://
CRAN.R-project.org/package=rms).
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